Berberine reduces LDL by 15–25% through PCSK9 inhibition and LDLR upregulation via a statin-independent pathway. While promising, evidence is primarily from small Chinese RCTs; no large cardiovascular outcomes trial exists to date.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.